The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
An article from
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
Published June 5, 2026
The Supreme Court ruled June 4, 2026 against Amarin in a case in which it alleged Hikma Pharmaceuticals had infringed on patents protecting its heart drug Vascepa.
Fintan Trimble via Getty Images
US supreme court backs generic drugmaker over Irish-American firm in patent case
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Supreme Court backs generic drugmaker in 'skinny labeling' case
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
Treatment for millions at stake in 'skinny label' Supreme Court case
Supreme Court backs generic drugmaker in patent case
Supreme Court sides with Hikma in 'skinny label' case
Will Makary's FDA voucher program survive?
Axsome fends off generic competition to narcolepsy med Sunosi until 2040
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with…
With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma…
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research…
A unanimous court ruled that a copycat version of a heart drug didn't infringe on the brand-name equivalent's patents.
